Navigation Links
Braeburn Pharmaceuticals Applauds Repeal of HB2
Date:3/31/2017

PRINCETON, N.J., March 31, 2017 /PRNewswire/ -- Braeburn Pharmaceuticals, Inc. made the following statement today in response to the repeal of House Bill 2 (HB2).

"Diversity and a commitment to inclusion is core to the identity of Braeburn Pharmaceuticals. Last year, we decided to proceed with plans to develop a research facility in Durham County despite our deep concerns and opposition to HB2, vowing to do our part to help overturn it," said President and CEO Behshad Sheldon, Braeburn Pharmaceuticals. "We applaud Governor Cooper and legislative leaders for passing a compromise solution that removes HB2 and takes an important step to protect the rights of all citizens in North Carolina. We will continue to advocate for progressive public policy and support those who share our commitment to diversity and nondiscrimination."

About Braeburn Pharmaceuticals

Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in neuroscience. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges. Braeburn's commercial product, Probuphine® (buprenorphine) implant was approved by the FDA in May 2016. Braeburn's investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Braeburn's pipeline products are at various stages of clinical development and include weekly and monthly CAM2038, subcutaneous injection depot formulations of buprenorphine, being investigated in opioid addiction and pain, BB0417 buprenorphine/granisetron injectable for acute pain, and BB0817, six-month risperidone implant being investigated in schizophrenia. More information on Braeburn can be found at www.braeburnpharmaceuticals.com.

Contacts:

Sherry Feldberg for Braeburn Pharmaceuticals
MSLGROUP
781-684-0770
braeburnpharma@mslgroup.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/braeburn-pharmaceuticals-applauds-repeal-of-hb2-300432936.html


'/>"/>
SOURCE Braeburn Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Fast Company Honors Braeburn Pharmaceuticals as a Top Ten Most Innovative Company in Biotech
2. Braeburn Pharmaceuticals and CEO Behshad Sheldon Win Stevie Awards for Best New Product or Service and Female Executive of the Year
3. Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain
4. Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction
5. Braeburn Pharmaceuticals and Camurus announces start of Phase 3 trial of long-acting buprenorphine treatments for opioid dependence
6. Braeburn Pharmaceuticals And Titan Pharmaceuticals Announce Date Of FDA Advisory Committee Review Of Probuphine For Opioid Addiction
7. Dr. Frank Young of Braeburn Pharmaceuticals Receives 2015 Distinguished Scientist Award from American College of Toxicology
8. Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments
9. Panacea Pharmaceuticals, Inc. Presents Data That Its Cancer Biomarker HAAH is Readily Detectable in Serum Exosomes
10. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Synergy Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
11. Glenmark Pharmaceuticals Reports Positive Results from a Phase 3 Trial of GSP 301, Mometasone/Olopatadine Fixed-Dose Combination Nasal Spray, in Seasonal Allergic Rhinitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2019)... , ... August 16, 2019 , ... ... has received FDA approval, providing an alternative that both corrects the curve and ... which uses patented methods and techniques developed by medical staff of Shriners Hospitals ...
(Date:8/16/2019)... ... August 16, 2019 , ... ... (BAPAI) that could potentially treat treatment-resistant hypertension by acting in the brain to ... 150 million people worldwide that are affected by treatment-resistant hypertension, resulting in almost ...
(Date:8/16/2019)... ... August 16, 2019 , ... OCT ... announced it has successfully completed enrollment of 690 patients for a phase III ... ranging, multicenter, randomized, double-blind, placebo-controlled, home use, parallel group clinical trial of MED2002, ...
Breaking Medicine Technology:
(Date:8/16/2019)... ... August 16, 2019 , ... ... custom handcrafted, one-of-a-kind children’s aircraft to Ronald McDonald House Charities in New Hyde ... children residents undergoing medical treatments and their family members a comfortable and fun ...
(Date:8/16/2019)... ... August 16, 2019 , ... Dr. Demetri Arnaoutakis, a ... Haute Beauty Network. , The Haute Beauty Network, well known for its exclusive ... a hair restoration expert and our newest addition to the Haute Beauty members-only ...
(Date:8/15/2019)... ... August 15, 2019 , ... The ... who have been directly affected by the closure of Hahnemann University Hospital in ... during the campaign, the ASCP Foundation will be making hardship grants of up ...
(Date:8/15/2019)... ... August 15, 2019 , ... Jon ... deadline for family planning clinics to provide written assurance that they will comply ... Similar to the Global Gag Rule, the new policy restricts providers and clinics ...
(Date:8/14/2019)... ... August 14, 2019 , ... Teguar Corporation has claimed ... America. This list has long-been established as a mark of success for some of ... and Oracle. Teguar made the list in 2015, 2016 and 2017. This year, Teguar ...
Breaking Medicine News(10 mins):